Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

SELLAS Life Sciences (SLS) Operating Expenses (2019 - 2024)

SELLAS Life Sciences (SLS) has disclosed Operating Expenses for 9 consecutive years, with $6.9 million as the latest value for Q4 2024.

  • Quarterly Operating Expenses fell 15.4% to $6.9 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $31.5 million through Dec 2024, down 16.78% year-over-year, with the annual reading at $28.3 million for FY2025, 10.28% down from the prior year.
  • Operating Expenses for Q4 2024 was $6.9 million at SELLAS Life Sciences, down from $7.3 million in the prior quarter.
  • The five-year high for Operating Expenses was $17.7 million in Q1 2022, with the low at $4.1 million in Q1 2020.
  • Average Operating Expenses over 5 years is $8.2 million, with a median of $7.8 million recorded in 2021.
  • The sharpest move saw Operating Expenses skyrocketed 123.22% in 2022, then crashed 36.39% in 2023.
  • Over 5 years, Operating Expenses stood at $6.1 million in 2020, then skyrocketed by 91.76% to $11.6 million in 2021, then fell by 18.7% to $9.4 million in 2022, then dropped by 13.43% to $8.2 million in 2023, then dropped by 15.4% to $6.9 million in 2024.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $6.9 million, $7.3 million, and $7.6 million for Q4 2024, Q3 2024, and Q2 2024 respectively.